Trulieve Stock Surges 18% on Strong Q1 2026 Earnings Beat
TL;DR Trulieve (TCNNF) crushed Q1 estimates with revenue of $285M, up 22% year-over-year. Operating margins improved to 18.2%, and the company reiterated full-year guidance of $1.15B-$1.2B in revenue.
By Sheeba M. | April 6, 2026
Q1 Numbers Exceed Expectations
Trulieve Cannabis Corp. (TCNNF) reported first-quarter 2026 earnings that Wall Street didn't see coming. Revenue came in at $285 million, representing a 22% increase from the same period last year and surpassing analyst estimates by $12 million. The company's operational efficiency continued to improve, with adjusted EBITDA reaching $52 million—a 34% jump year-over-year.
The Florida-based cannabis operator has been executing its geographic expansion strategy while maintaining disciplined cost controls. CEO Kim Rivers highlighted that the company's vertical integration model continues to drive margins higher across all markets.
Florida Market Shows Continued Strength
Florida remains Trulieve's crown jewel, contributing $198 million in revenue for the quarter. Medical marijuana patient registrations continued climbing, reaching 850,000 active patients as of March 2026. The company operates 127 dispensaries across the Sunshine State and holds a dominant 40% market share.
With adult-use marijuana legalization expected to appear on Florida's November 2026 ballot, Trulieve is positioning itself as the primary beneficiary of potential recreational expansion. Industry analysts estimate that adult-use sales could add $400-600 million annually to the state's legal cannabis market.
Balance Sheet Reinforced
Trulieve ended Q1 with $340 million in cash and equivalents, providing ample flexibility for continued growth investments. Total debt stands at $890 million, representing a leverage ratio of 1.7x adjusted EBITDA—still within comfortable territory for a high-growth cannabis company.
The company generated $38 million in free cash flow during the quarter, a significant improvement from negative FCF in Q1 2025. This marks the fourth consecutive quarter of positive free cash flow, demonstrating the business' path to sustainable profitability.
Full-Year Guidance Reiterated
Management maintained its 2026 revenue guidance of $1.15 billion to $1.2 billion, representing approximately 20% growth from 2025. The company expects adjusted EBITDA margins to expand by an additional 150-200 basis points throughout the year as operational efficiencies compound.
Trulieve is also eyeing strategic acquisitions in Ohio and Pennsylvania, two states where it currently has limited presence. The company has allocated $75 million for M&A activities in 2026.
Analyst Reaction and Price Targets
Following the earnings release, eight analysts raised their price targets on TCNNF. The average price target now sits at $21.50, representing 35% upside from current levels. Cantor Fitzgerald analyst Pablo Zuanic maintained an Overweight rating with a $24 price target, calling Trulieve "the best-in-class MSO with a clear path to cash flow positivity."
Zuanic noted that Trulieve's Florida dominance combined with its expansion strategy makes it "uniquely positioned to capture market share as federal cannabis reform eventually materializes."
Track TCNNF: TCNNF Stock Tracker
Related: Curaleaf (CURLF) | Green Thumb Industries (GTBIF)